Abionyx Pharma (XPAR:ABNX) COGS-to-Revenue : 0.75 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma COGS-to-Revenue?

Abionyx Pharma's Cost of Goods Sold for the six months ended in Dec. 2023 was €1.88 Mil. Its Revenue for the six months ended in Dec. 2023 was €2.51 Mil.

Abionyx Pharma's COGS to Revenue for the six months ended in Dec. 2023 was 0.75.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Abionyx Pharma's Gross Margin % for the six months ended in Dec. 2023 was 25.04%.

Abionyx Pharma COGS-to-Revenue Historical Data

The historical data trend for Abionyx Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma COGS-to-Revenue Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.62

0.88

0.87

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.64	0.97	0.79	1.01	0.75

Abionyx Pharma COGS-to-Revenue Calculation

Abionyx Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.022	/	4.64
	=	0.87

Abionyx Pharma's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.883	/	2.512
	=	0.75

Abionyx Pharma (XPAR:ABNX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Abionyx Pharma's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.883 / 2.512
	=	25.04 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Abionyx Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (XPAR:ABNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines